Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTI-1601 SAD in Friedreich's Ataxia
NCT04176991Phase 1Completed
- Sponsor
- Larimar Therapeutics
- Start
- Dec 2019
- Primary completion
- Oct 2020
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Friedreich's ataxia (FA) comparing CTI-1601 with Placebo (2 arms). Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events and Number of Treatment Emergent Adverse Events by System Organ Classification and Preferred Term. Started Dec 2019; status: completed.
02
Drugs
nomlabofusp
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT04176991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176991.